I
Immunos Therapeutics
Developing the next generation of novel immunotherapies that will improve the lives of patients with serious diseases
About Immunos Therapeutics
ImmunOs Therapeutics is a biotech startup that operates in the healthcare sector, specifically in the development of novel immunotherapies for the treatment of cancer and autoimmune diseases. Their business model revolves around the identification of specific human leukocyte antigen (HLA) molecules that can hyper-activate the immune system of patients with severe autoimmune disorders.
Read full description
The company has leveraged this discovery to create an HLA-based technology platform. This platform is used to generate a new class of biologic therapeutics, which are essentially drugs derived from living organisms that are used to treat diseases and medical conditions. Their primary clients are patients suffering from cancer and autoimmune diseases.
ImmunOs Therapeutics has a lead program, IOS-1002, which has shown therapeutic efficacy in preclinical studies both as a standalone treatment and in combination with standard cancer therapies. The company's mission is to improve the lives of patients with serious diseases by developing the next generation of novel immunotherapies.
The company has also established a comprehensive data set of validated results, thanks to a global team of experts in immunotherapy, immunology, and oncology. They have also entered into a clinical trial collaboration with Merck, a multinational pharmaceutical company, which could potentially boost their market reach and credibility.
In terms of revenue, ImmunOs Therapeutics likely makes money through the development and commercialization of their novel immunotherapies, as well as through strategic partnerships with larger pharmaceutical companies like Merck.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Zurich, Switzerland
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 73.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Business Development, Biotechnology, Oncology, Drug Development, Research and Development, Immune System, Spinout, Alternative Protein, Digital Therapeutics, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2024 | $8.5M | $325M | Gimv · Pfizer Ventures · Double Point Ventures · BioMedVC | ↗ |
| SERIES BOther financing | Jun 2022 | $65M | $260M | GL Capital · Pfizer Ventures · Mission BioCapital · Gimv | ↗ |
Growth signals
Latest recorded traffic for Immunos Therapeutics is 630 monthly website visits, up 425% over the last three months. Immunos Therapeutics's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Schroder Adveq
UZH Life Sciences Fund
BioMedVC- PVPfizer Ventures
Gimv
Lightspeed Venture Partners
Samsara BioCapital- GCGL Capital
Mission BioCapital
PEAK6- FFFiscus Financial
Series B and later1 investor entered at this stage
Double Point Ventures
Other known investors2 additional known investors
University of Basel
University of Zürich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.